Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. Talamonti MS, et al. Among authors: philip pa. Ann Surg Oncol. 2006 Feb;13(2):150-8. doi: 10.1245/ASO.2006.03.039. Epub 2006 Jan 19. Ann Surg Oncol. 2006. PMID: 16418882 Free article. Clinical Trial.
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Small W Jr, et al. Among authors: philip pa. J Clin Oncol. 2008 Feb 20;26(6):942-7. doi: 10.1200/JCO.2007.13.9014. J Clin Oncol. 2008. PMID: 18281668 Clinical Trial.
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Katz MH, et al. JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17. JAMA Surg. 2016. PMID: 27275632 Free PMC article. Clinical Trial.
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
Al-Sukhun S, Zalupski MM, Ben-Josef E, Vaitkevicius VK, Philip PA, Soulen R, Weaver D, Adsay V, Heilbrun LK, Levin K, Forman JD, Shields AF. Al-Sukhun S, et al. Among authors: philip pa. Am J Clin Oncol. 2003 Dec;26(6):543-9. doi: 10.1097/01.coc.0000037143.60502.54. Am J Clin Oncol. 2003. PMID: 14663369 Clinical Trial.
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
El-Rayes BF, Zalupski M, Shields AF, Manza SG, LoRusso P, Philip PA. El-Rayes BF, et al. Among authors: philip pa. Am J Clin Oncol. 2007 Apr;30(2):101-5. doi: 10.1097/01.coc.0000251223.98193.f4. Am J Clin Oncol. 2007. PMID: 17414457 Clinical Trial.
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Bauer TM, et al. Among authors: philip pa. Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11. Cancer. 2013. PMID: 22786786 Free PMC article.
362 results